J&J, Genmab deal

Genmab will receive a $25 million milestone payment from Johnson & Johnson’s Janssen Biotech Inc. unit under an August 2012 deal granting the unit exclusive, worldwide rights to daratumumab. The milestone, the third under the deal, was triggered by undisclosed progress in an ongoing Phase III trial comparing daratumumab plus lenalidomide and dexamethasone vs. lenalidomide and dexamethasone alone in patients with relapsed or refractory multiple myeloma (MM). Genmab declined disclose what specifically triggered the milestone, and Janssen could not be reached. ...